Skip to main content

Advertisement

SpringerLink
Log in

Future directions in tumor immunotherapy: CTLA4 blockade

  • Viewpoint
  • Published:

From Nature Clinical Practice Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Leach DR et al. (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734–1736

    Article  CAS  Google Scholar 

  2. Mueller DL et al. (1989) Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 7: 445–480

    Article  CAS  Google Scholar 

  3. Waterhouse P et al. (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270: 985–988

    Article  CAS  Google Scholar 

  4. Quezada SA et al. (2006) CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116: 1935–1945

    Article  CAS  Google Scholar 

  5. Zeh HJ III et al. (1999) High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 162: 989–994

    CAS  PubMed  Google Scholar 

  6. Hodge JW et al. (2005) Multiple costimulatory modalities enhance CTL avidity. J Immunol 174: 5994–6004

    Article  CAS  Google Scholar 

  7. Attia P et al. (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23: 6043–6053

    Article  CAS  Google Scholar 

  8. Small E et al.; A phase I trial of CTLA-4 blockade with human anti-CTLA-4 (MDX-010) in patients with hormone refractory prostate cancer. Clin Cancer Res, in press

  9. Fong L et al. (2006) A phase I trial of combination immunotherapy with CTLA-4 blockade and GM-CSF in hormone-refractory prostate cancer [abstract]. J Clin Oncol 24: 2508

    Google Scholar 

  10. Gerritsen W et al. (2006) A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC) [abstract]. J Clin Oncol 24: 2500

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. JL Gulley is Director of the Clinical Immunotherapy Group at the Laboratory of Tumor Immunology and Biology, and WL Dahut is Chief of the GU/GYN Clinical Research Section in the Medical Oncology Branch, the National Cancer Institute, Bethesda, MD, USA.,

    James L Gulley & William L Dahut

Authors
  1. James L Gulley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William L Dahut
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William L Dahut.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gulley, J., Dahut, W. Future directions in tumor immunotherapy: CTLA4 blockade. Nat Rev Clin Oncol 4, 136–137 (2007). https://doi.org/10.1038/ncponc0749

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0749

  • Springer Nature Limited

Search

Navigation